(Antonaci F., et al. AuraSTOP in the treatment of migraine aura. International Journal of Neurology and Brain Disorders. 2018
ISSN 2377-1348) Currency AuraSTOP® in the clinical setting of treatment at the time of the attack of a migraine aura.
This study evaluated AuraSTOP® in the clinical management of migraine aura when taken at the onset of symptoms., mainly visual (scotomas, sparkles, alterations of the visual field), but sometimes also sensitive or language, which precede or accompany the painful phase. The pathophysiological mechanism underlying the aura is generally identified in the cortical spreading depression (CSD), a neuronal depolarization wave that propagates at the cortical level, causing temporary alterations in activity cerebral.
AuraSTOP® is a nutraceutical combination composed of Tanacetum parthenium (titled in parthenolide), 5-hydroxytryptophan (5-HTP) by Griffonia simplicifolia and magnesium. The rationale for the use of this formulation is based on the biological properties of its components: the Tanacetum Parthenium exerts an anti-inflammatory action and modulates the release of neuropeptides involved in migraine pathophysiology; 5-HTP contributes to the regulation of the serotonergic system, often altered in patients with migraines; Magnesium plays a key role in stabilizing neuronal membranes and controlling cortical hyperexcitability, potentially implicated in CSD.
The study evaluated patients with migraines with Aura who took AuraSTOP® at the onset of symptoms. The main endpoints included the duration of the aura and the possible prevention or attenuation of the subsequent painful phase. The results show a significant reduction in the duration of the aura in subjects treated early, with a significant share of subjects who also reported a reduction in the intensity of the headache or its failure to appear.
Treatment was generally well tolerated, with no serious side effects and good compliance by patients. The authors point out that timely intake at the time of the onset of the aura could represent a crucial element to maximize the effectiveness of the product.
In conclusion, the study suggests that AuraSTOP<sup>®</sup> may represent a safe and potentially effective option for supporting patients with migraine aura, offering a targeted approach to the neurobiological mechanisms underlying this phenomenon. However, randomized controlled clinical trials are needed to confirm its efficacy and to better define the role of this combination in relation to conventional pharmacological therapies.
Limitations: despite being a relatively large case study, the results should be interpreted with caution due to the uncontrolled observational nature, the lack of confrontation with placebo or other therapies, the possible subjective variability in patient diaries and the absence of long-term follow-up
(Dal Volta G., et al. Efficacy of a combination of tanacetum parthenium, 5-hydroxy triptohan and magnesium (AuraSTOP) in the prevention of high frequency migraine with aura. Open Access Library. 2018;5,E4939)
(Dal Volta G., et al. Comparison of the effect of Tanacethum parthenium, 5-hydroxy tryptophan, and magnesium (AuraSTOP) versus magnesium alone on aura phenomenon and ITS Evolution. Pain Research and Management. 2019;6320163)
(Mainardi F., et al. Efficacy of a combination of tanacetum parthenium, 5-hydroxy tryptohan and magnesium (AuraSTOP) in Episodic migraine prevention: a multicentric Observational Study Open Access Library Journal 2018;5,E4765).
(Ferrare P., et A. Tanacetum, Parthenium, Griffonia simplicifolia and magnesium as symptomatic and prophylactic treatment for headache in Paediatric Patients. International Journal of Neurology and Braind Disorders ISSN 2377-1348).

